CORDIS
EU research results

CORDIS

English EN
Development and clinical trials of a new Software ENgine for the Assessment & Optimization of drug and non-drug Therapy in Older peRsons

Development and clinical trials of a new Software ENgine for the Assessment & Optimization of drug and non-drug Therapy in Older peRsons

Objective

The European population of older people with multiple chronic diseases (multimorbidity) is increasing steadily in tandem with the rising population of people aged ≥ 65 years. Older multimorbid people are at high risk of polypharmacy (PP), inappropriate prescribing (IP), adverse drug reactions (ADRs) and adverse drug events (ADEs). PP, IP, ADRs and ADEs in turn cause excessive drug costs and excess healthcare utilization; ADRs and ADEs also cause significant mortality. The current rapid rise in drug expenditure relating mostly to drug use by older people across Europe is not economically sustainable. In tandem with the drug therapy problems, there is underuse of non-drug therapies i.e. physiotherapy, occupational therapy, speech & language therapy, nutritional therapy, psychotherapy in the treatment of chronic diseases in this cohort. Optimal management of drug and non-drug therapy in older multimorbid persons usually requires specialist skill, but most doctors who treat older people do not have specialist training in Geriatric Medicine. To address these challenges, we propose to design and build a software engine (SENATOR) with the capacity to optimize therapy and simultaneously minimize ADRs, IP, PP and excessive cost. SENATOR will evaluate drug indications and contraindications, ADR/ADE risk and detect IP using validated criteria. SENATOR will identify cheapest drug brands to minimize cost. SENATOR will also recommend appropriate symptom-focused drug therapy and avoidance of drugs unlikely to be beneficial in frailer older people with low one year life expectancy. In addition, SENATOR will provide specific advice on appropriate non-drug therapies for individual patients. To test SENATOR’s efficacy, we will perform a multicentre RCT involving 1800 older multimorbid patients hospitalized with acute illness under the care of specialists other than geriatricians, using ADR incidence, medication appropriateness and drug/healthcare costs as the main outcome measures.

Coordinator

UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK

Address

Western Road
T12 Yn60 Cork

Ireland

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 758 126

Administrative Contact

David O'connell (Dr.)

Participants (12)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITEIT GENT

Belgium

EU Contribution

€ 547 343

CLANWILLIAM HEALTH LIMITED

Ireland

EU Contribution

€ 584 994

SERVICIO MADRILENO DE SALUD

Spain

EU Contribution

€ 599 819

ISTITUTO NAZIONALE DI RIPOSO E CURA PER ANZIANI INRCA

Italy

EU Contribution

€ 675 000

UNIVERSITY OF EAST ANGLIA

United Kingdom

EU Contribution

€ 189 600

LANDSPITALI UNIVERSITY HOSPITAL

Iceland

EU Contribution

€ 525 024

HASKOLI ISLANDS

Iceland

EU Contribution

€ 23 210,14

GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG

Germany

EU Contribution

€ 148 537,02

CLININFO SA

France

EU Contribution

€ 85 300

GRAMPIAN HEALTH BOARD

United Kingdom

EU Contribution

€ 631 587

SYDDANSK UNIVERSITET

Denmark

EU Contribution

€ 3 944,70

ARTTIC

France

EU Contribution

€ 166 462,14

Project information

Grant agreement ID: 305930

Status

Closed project

  • Start date

    1 October 2012

  • End date

    30 June 2018

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 805 965,07

  • EU contribution

    € 5 938 947

Coordinated by:

UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK

Ireland